Genmab’s Strategic Forecast and Pipeline Potential Drive Buy Rating

Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on 0MGB stock, giving a Buy rating on May 13.

Sachin Jain has given his Buy rating due to a combination of factors including Genmab’s strategic forecast changes and potential growth prospects. The company has updated its financial forecasts to reflect currency changes, which have minimal impact on earnings per share, but the valuation remains attractive. The potential upside from Genmab’s mid-term pipeline, particularly with key assets like Acasunlimab, Rina-S, and Epkinly, is a significant factor in the Buy rating.
Sachin Jain also highlights the importance of upcoming data releases and milestones in 2025 and 2026, which are expected to provide greater clarity on growth prospects. The anticipated data from late-stage pipeline developments and the ongoing success of Darzalex provide a clearer growth pathway, supporting the Buy recommendation. The company’s valuation, alongside these growth drivers, reinforces the positive outlook for Genmab’s stock.

Jain covers the Healthcare sector, focusing on stocks such as Novo Nordisk, AstraZeneca, and Sanofi. According to TipRanks, Jain has an average return of 0.4% and a 49.61% success rate on recommended stocks.

In another report released on May 13, Barclays also maintained a Buy rating on the stock with a DKK1,875.00 price target.